

Compromiso con el Progreso

Reporte de Impacto de MSD 2024/2025

Para el reporte completo [hacé click aquí](#).

"Nuestro compromiso y enfoque de largo plazo para promover el acceso a la salud, operar de manera responsable e implementar estrategias que protejan la salud de las personas, los animales y el planeta es firme. Mientras seguimos enfrentando el rápido ritmo de los cambios que ocurren a nuestro alrededor, me siento orgulloso del progreso que hemos logrado hasta ahora y mantengo el optimismo sobre nuestro futuro."



Robert M. Davis
Chairman &
Chief Executive Officer



Key highlights

Acceso a la salud

>450 millones

Personas alcanzadas con nuestras vacunas y medicinas en 2024¹

>247 millones

Personas accedieron a nuestras vacunas y medicamentos innovadores a través de soluciones de acceso en 2024²

Empleados

>25.000

Empleados son miembros de al menos uno de nuestros 10 Grupos de Recursos Comerciales para Empleados; esto representa más del 30 % de nuestra fuerza laboral a nivel mundial. Todos los empleados están invitados a unirse a cualquiera de nuestros Grupos de Recursos Empresariales para Empleados.

>75

De los países tienen acceso a nuestro Programa Global de Asistencia al Empleado (EAP), que ofrece un apoyo integral en salud mental para nuestros empleados y sus familias.

Sostenibilidad Ambiental

Net-zero

Comprometidos con un objetivo de emisiones netas cero de gases de efecto invernadero (GEI) en todas nuestras operaciones globales (Alcances 1, 2 y 3) para 2045, alineado con las directrices de la iniciativa de Objetivos Basados en la Ciencia (SBTi).

400+

Colaboraciones con proveedores en apoyo a nuestros esfuerzos para reducir las emisiones de gases de efecto invernadero (GEI). (60 % de nuestras emisiones de scope 3 en 2023).

Ética & Valores

24/7

Disponibilidad de nuestra herramienta de reporte [MSDethics.com](#), la cual permite tanto a empleados como a terceras partes elevar preocupaciones o comentarios de manera anónima (donde la ley lo permita)

\$4.000 millones

Inversión en proveedores globales diversos de Tier 1 y 2 en 2024 para propender una cadena de suministro saludable

Áreas de enfoque, metas y desempeño en sostenibilidad

Operamos de manera responsable todos los días para garantizar un futuro seguro, sostenible y saludable para las personas y las comunidades en todo el mundo. Nuestras metas reflejan nuestros compromisos públicos de generar valor tanto para la sociedad como para nuestro negocio. En el último año, nos hemos desafiado a nosotros mismos para lograr avances significativos en el cumplimiento de nuestros ambiciosos compromisos en cada una de nuestras áreas de enfoque: Acceso a la Salud, Empleados, Sostenibilidad Ambiental, y Ética y Valores.³

Acceso a la Salud

Metas	2023	2024	Total
Alcanzar a 50 millones de personas en países de ingresos bajos y medianos (LMICs) y personas desatendidas por la atención médica en países de ingresos altos con nuestras inversiones sociales, para 2025 ^{4,5}	21.2	11.4	66.2
Alcanzar al menos el 75% de los países en el mundo anualmente con nuestros productos. ^{6,7}	79%	92%	
Permitir que 350 millones de personas más accedan a nuestros medicamentos y vacunas innovadoras a nivel mundial para 2025. ²	240.0	247.7	

Sostenibilidad Ambiental

Metas	2023	2024
Reducir nuestras emisiones operativas de GEI* (i.e., Scopes 1 & 2) 46% hacia 2030, desde la base del 2019 ⁹	14% debajo de la base	16% debajo de la base
Reducir GEI en la cadena de valor (Scope 3) en un 30% para 2030, con base al 2019. ^{10,11}	9% debajo de la base	6% debajo de la base
baseContar con el 100% de nuestra electricidad adquirida de fuentes renovables para el 2025. ¹²	57%	61%
Cero emisiones de gases de efecto invernadero (Scopes 1, 2 & 3) al 2045	En 2024, nos comprometimos a un target de cero impacto al 2045 entre todas nuestras operaciones globales (GHG emissions Scope 1, 2 & 3) alineado con las guías de SBTi.	

*GEI: Gases de Efecto Invernadero

Empleados

Metas	2023	2024
Mantener o incrementar el compromiso de nuestros empleados al 2025 ⁸	On track	On track
Mantener o incrementar nuestro índice de inclusión al 2025 ⁸	On track	On track

Ética & Valores

Metas	2023	2024
Fomentar una cultura de "Alzar la Voz" manteniendo o superando nuestro porcentaje actual de empleados a nivel mundial que responden favorablemente a la pregunta de "Dispuesto a informar" en la encuesta interna, para 2025 ¹³	On track	On track
Cumplimiento al 100% en requisitos de privacidad y protección de datos para el monitoreo activo de incidentes, análisis de riesgos/daños y notificación a tiempo de violaciones de datos. ¹⁴	100% compliance maintained	100% compliance maintained

Premios y Reconocimientos

Estamos orgullosos de que nuestro compromiso de larga data con la promoción de acciones responsables haya recibido reconocimiento externo, mientras nos esforzamos por mitigar los riesgos relacionados con la sostenibilidad y crear valor para nuestro negocio, la sociedad y todos nuestros grupos de interés.

Sostenibilidad

Newsweek & Statista

Clasificada en el #1 de la lista de las empresas más responsables de América, y #1 en el sector de Salud y Ciencias de la Vida, ocupando el primer lugar por segundo año consecutivo (2024, 2025)

TIME

Clasificada en el #28 de la lista de las empresas más sostenibles del mundo (2024)

JUST Capital/CNBC

Clasificada en el #41 de la lista de las empresas más justas de América, y #2 en el sector de farmacéutica y biotecnología (2025)

Liderazgo Corporativo & Management

Wall Street Journal

Clasificada en el #33 de la lista de las 250 empresas estadounidenses que cotizan en bolsa y están mejor gestionadas (2024)

Fortune

Clasificada en el #68 de la lista de las 100 mejores empresas para trabajar (2024)

Forbes

Clasificada en el #97 de la lista de los mejores empleadores, de más de 700 empresas (2025)



Notas

¹ This people reached metric estimates the number of people who have received a company product through commercial channels, clinical trials, voluntary licensing or product donations. Product donations include people reached through the MECTIZAN Donation Program, U.S. Patient Assistance Programs, and the MSD Medical Outreach Program. Sources of data are Merck & Co., Inc., Rahway, NJ, USA and third-party data sets that are tracked within an enterprise-wide internal database. The people reached metric for all sources is calculated as doses sold divided by the average dose schedule for a given market in a given year. People taking multiple products may be counted as multiple people toward the total estimate. In some instances, this estimate may include people enabled to access our products through access solutions, which are calculated as part of our goal to enable access to our innovative medicines and vaccines. The people reached metric does not include people reached through social investments, which are calculated as part of our goal to further advance access to health for populations in LMICs and groups with limited access to care in high-income countries.

² The number displayed is for the year 2024 and provides information on the number of additional people who we estimate now have the option to access medicines and vaccines as a result of our sustainable access strategies, solutions and partnerships. These solutions include our commitment to Gavi and UNICEF (rather than doses shipped), collaborations to optimize resources in health systems, expanded financial coverage through insurance, and new community-based channel partnerships. “Innovative medicines and vaccines” refers to our Company’s on-patent products. Enable “more people” is defined as populations supported by initiatives implemented and launched in market and will be in comparison to the baseline (2020) as of 2025. Evidence for metrics is sourced from publicly available data and proxy sources by market. While proxies differ by market, all methodologies are evaluated and represent our best estimate of people enabled to access innovative medicines and vaccines. People who were enabled to access innovative medicines and vaccines did not necessarily receive such innovative medicines and vaccines.

³ Our Company’s strategic framework.

⁴ Social investments include our Company’s philanthropic partnerships, programs and impact investments. Underserved populations are defined as those that face health disparities due to disadvantages related to insurance status, social determinants of health, race, ethnicity, gender identity/sexual orientation, age and/or language preference. The goal is cumulative across the reporting period of 2021-2025 and is independent of a baseline period. Actuals for each year to date are based on reports received between the 1st of March and the last day of February of the corresponding performance year.

⁵ Third-party reporting is used to calculate the number of people reached through social investments. In some cases, third-party reports may include cumulative people reached for the reporting period, and/or data that is attributable to other partners as well as our Company’s philanthropic investment.

⁶ Countries are as defined by the World Bank Country and Lending Groups. Includes only human health products.

⁷ Reflects improved data capture through updated processes that now include previously unreported markets.

⁸ In 2022, we revised employee survey measurements to align with evolving best practices. In this report, 2022 data are used as the baseline for future comparison.

⁹ Scope 1 GHG emissions are direct emissions from owned or controlled sources such as on-site fuel combustion and fleet vehicles. Scope 2 GHG emissions are indirect emissions from the generation of purchased energy consumed by the reporting company.

¹⁰ Scope 3 GHG emissions include all other indirect emissions in a company’s value chain.

¹¹ In 2024, we initiated a work process with our suppliers to collect and report their activity data related to our Scope 3 emissions in place of our input/output spend modeled data, when available. Our 2019-2024 Scope 3 performance data and goals were updated to include this data.

¹² We have defined “purchased electricity” as electricity sourced from external suppliers as well as renewable electricity that was generated and utilized on site where we retained the renewable attributes or where we have obtained renewable attributes through contract.

¹³ Favorable response indicates the percentage of respondents who respond “yes” to the question stating, “I am willing to report employee misconduct and potential ethics or compliance issues.”

¹⁴ Regulatory requirements differ by region.



Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved.

Forward-looking statement

This publication of Merck & Co., Inc., Rahway, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No duty to update

The information contained in this publication was current as of the date presented. The Company assumes no duty to update the information to reflect subsequent developments. Consequently, the Company will not update the information contained in this publication and investors should not rely upon the information as current or accurate after the presentation date.

Merck & Co., Inc.
126 East Lincoln Avenue
P.O. Box 2000
Rahway, NJ 07065 USA
MSD.com

Merck & Co., Inc., Rahway, NJ, U.S.A., is known as MSD outside the United States and Canada.